Translate page

× To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML cases here. Physicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("New Discussion" button below). Please include the country of origin.

Each clinical case will be forwarded to the expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity. Please consider including your email with the case. This will not be posted on the website, but is useful should further details be requested by the moderator.

As a full clinical history is necessary for accurate comment, cases and comments on the Forum are ONLY ACCEPTED FROM PHYSICIANS. If individual patients have a specific question we encourage them to contact their healthcare provider. General questions can be emailed to info@cml-foundation.org.

DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.

Molecular monitoring

  • Akhil Biswas
  • Akhil Biswas's Avatar Topic Author
1 day 22 hours ago #2101 by Akhil Biswas
Replied by Akhil Biswas on topic Molecular monitoring
Given expression of two BCR-ABL1 transcript, I would prefer to monitor by P210 if monitoring facility for both transcript is not available, as P210 is likely to by the transcript of primary clone. However, considering that p190 is coming from a subclone, I would prefer to do hematological monitoring by CBC more frequently, may be monthly to detect any probable hematological relapse from that subclone.
Moderators: Nicolaarlene